Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigation
ConclusionsTaken together, the extracts we present from internal company documents illustrate implementation of a strategy at odds with unbiased study conduct and dissemination. Our findings suggest that Pfizer and Parke-Davis’s publication strategy had the potential to distort the scientific literature, and thus misinform healthcare decision-makers.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439687/?report=classic
Source: PharmaGossip - Category: Pharma Commentators Authors: insider Source Type: blogs
More News: Bipolar | Clinical Trials | Gabapentin | Headache | Health | Insurers | Mania | Migraine | Neurology | Neurontin | Neuroscience | Pain | Pfizer | Pharma Commentators | Study